Vaxxas, a biotechnology company commercializing a novel vaccination platform, announced Merck, known as MSD outside of the United States and Canada, has exercised its option to utilize Vaxxas’ proprietary High Density Microarray Patch (HD-MAP) platform for a vaccine candidate.
Pages
- Careers
- Certification of products subject to the requirements of the Consumer Product Safety Improvement Act of 2008 (CPSIA)
- Contact us
- Copyright
- Forward-looking statement
- ical
- Merck | Home
- Products list
- Responsible Vulnerability Disclosure Program of Merck & Co., Inc., Rahway, NJ, USA
- Sitemap
- Stories
- Terms of use
- What we do
- Who we are
- History
- Sustainability
- Environmental sustainability
- Impact Venture Fund
- Merck Medical Outreach Program
- Philanthropy
- Advancing equity in cancer care
- Advancing patient-centered cancer care
- Advancing patient-centered cancer care in resource-limited communities
- Enhancing diabetes care through community outreach and support
- Expanding access to cancer care in Asia
- Global emergency response
- Improving access to high-quality diabetes care
- Improving access to HIV care in sub-Saharan Africa
- Improving health care access
- Merck Foundation
- Merck Richard T. Clark Fellowship for Global Health
- Patient assistance and product donation programs
- Promoting equity in HIV/AIDS care
- Strengthening health systems’ resilience through immunization
- Strengthening our communities
- Sustainability resources
- Transparency disclosures
- Leadership
- Culture & values
- Diversity & inclusion
- Policies & positions
- Business development & licensing
- Suppliers
- Research
- Areas of focus
- Business development and licensing (BD&L)
- CHLOR-TRIMETON
- Immunology
- Meet our scientists
- Neuroscience
- Postdoctoral research fellows program
- Publications
- Scientific capabilities
- Vaccines
- COVID-19
- Infectious diseases
- Oncology
- Cardio-metabolic diseases
- Pipeline
- Discovery & development
- Clinical trials
- Diversity in clinical trials
- R&D locations
- Patients
- Investor relations
- Media
Archives
Categories
- No categories